Skip to main content
Figure 2 | Malaria Journal

Figure 2

From: Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine

Figure 2

Immune responses elicited by virosomal formulations of MSP-3 211-237 derived peptide-PE conjugates. Development of anti-peptide-PE IgG responses in peptide ELISA (A). Sown are halfmaximal IgG titers for individual animals and the geometric mean (line) after the second and third vaccination. Cross-reactivity of anti-peptide-PE IgG responses with cultured P. falciparum blood-stage parasites (B). Shown are individual IFA endpoint titers after the third immunization, lines representing the geometric mean. None of the pre-immune sera was positive in ELISA or IFA.

Back to article page